T315I-mutated myeloid sarcoma. (2019)

• Record Type: Journal Article
• Authors: Zhang, Yumeng; Swoboda, David M.; Grover, Aditya; Nodzon, Lisa; Zhang, Ling; Pinilla-Ibarz, Javier
• Is Part Of: Leukemia research reports. Volume 12(2019)
• Publication Date: 2019
• Subjects: T315I mutation -- Myeloid sarcoma -- Chronic myelogenous leukemia; Leukemia -- Periodicals; Lymphomas -- Periodicals; Multiple myeloma -- Periodicals; Leukemia -- Periodicals; Lymphoma -- Periodicals; Multiple Myeloma -- Periodicals; Hematologic Neoplasms -- Periodicals; Leukemia; Lymphomas; Multiple myeloma; Electronic journals; Periodicals; 616.9941905
• DOI: 10.1016/j.lrr.2019.100184
• Languages: English
• ISSNs: 2213-0489

Abstract

Abstract: Myeloid Sarcoma (MS) is diagnosed by an extramedullary proliferation of immature granulocytic cells. Its association with chronic myeloid leukemia (CML) is rare. CML is characterized by BCR-ABL1 gene rearrangement and therapies with tyrosine kinase inhibitors (TKI) are very effective. However, TKI resistance may occur secondary to the development of ABL1 mutations. T315I is a common mutation that accounts for ∼20% clinical resistance to TKIs. We report the first case of a patient with T315I mutated myeloid sarcoma that occurred after complete cytogenetic response with dasatinib of a chronic phase CML. The patient was successfully treated with induction chemotherapy and ponatinib.